| Literature DB >> 10462235 |
E P Rothstein1, E L Anderson, M D Decker, G A Poland, K S Reisinger, M M Blatter, R M Jacobson, C A Mink, D Gennevois, A E Izu, F Sinangil, A G Langenberg.
Abstract
Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject-blinded study, adults (> or = 18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10462235 DOI： 10.1016/s0264-410x(99)00164-4
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641